Caitlin John’s IGC Pharma IGC Stock Holding History

Caitlin John’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$53	Hold	200	–	–	﹤0.01%	924
2025 Q4	$56	Hold	200	–	–	﹤0.01%	912
2025 Q3	$83	Buy	+200	New	+$76	﹤0.01%	865
2025 Q1	–	Sell	-200	Closed	-$67	–	431
2024 Q4	$67	Hold	200	–	–	﹤0.01%	846
2024 Q3	$73	Hold	200	–	–	﹤0.01%	831
2024 Q2	$87	Hold	200	–	–	﹤0.01%	830
2024 Q1	$80	Hold	200	–	–	﹤0.01%	864
2023 Q4	$56	Buy	+200	New	+$62	﹤0.01%	879

Other funds holding IGC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lawood & Co Williamsport, Pennsylvania $148M AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caitlin John's IGC Position: Q1 2026 in Review

Caitlin John held its IGC Pharma (IGC) position steady in Q1 2026 at 200 shares worth $53. The position accounts for ﹤0.01% of the portfolio, ranked #924.

Caitlin John first reported a position in IGC in Q4 2023 and has held it in 8 quarters since. The position peaked at $87 in Q2 2024. 35 funds tracked by Wall St. Rank hold IGC as of Q1 2026.

Caitlin John held 200 shares of IGC Pharma worth $53 as of Q1 2026.
Caitlin John left its IGC Pharma share count unchanged in Q1 2026.
IGC Pharma made up ﹤0.01% of Caitlin John's portfolio in Q1 2026, its #924 holding.
Caitlin John first reported a position in IGC Pharma in Q4 2023 and has held it in 8 quarters since.
Caitlin John's IGC Pharma position peaked at $87 in Q2 2024.
35 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.